Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kristi Lin- Rahardja"'
Autor:
Manasi Kotulkar, Diego Paine-Cabrera, Sarah Abernathy, Dakota R. Robarts, Wendena S. Parkes, Kristi Lin- Rahardja, September Numata, Margitta Lebofsky, Hartmut Jaeschke, Udayan Apte
Publikováno v:
Hepatology.
Autor:
Roberto Vargas, Aaron Petty, Arda Durmaz, Kristi Lin-Rahardja, Ofer Reizes, Robert Debernardo, Jacob Scott
Endometrial cancer (EC) is the most common type of gynecologic malignancy in the United States, with over 65,950 new cases expected in 2022. Approximately 80% of cancer-related mortalities can be attributed to high-grade EC. Despite our ability to id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79279c116b14d402d429eb958aca263a
https://doi.org/10.1101/2022.09.06.505009
https://doi.org/10.1101/2022.09.06.505009
Publikováno v:
Cancer Research. 83:973-973
The evolution of chemotherapeutic resistance can cause treatment failure in patients with metastatic Ewings sarcoma (EWS), a rare pediatric bone cancer. As resistance to the first-line therapy evolves, there is potential for the tumor to develop sens
Publikováno v:
International Journal of Molecular Sciences. 24:6738
The ever-changing nature of cancer poses the most difficult challenge oncologists face today. Cancer’s remarkable adaptability has inspired many to work toward understanding the evolutionary dynamics that underlie this disease in hopes of learning
Autor:
Kalyani Chaubey, Kristi Lin-Rahardja, Andrew A. Pieper, Eric B. Taylor, Maria F. Noterman, Anjali M. Rajadhyaksha
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance The unique aspects of brain mitochondria composition and function are incompletely understood, and new approaches are required to understand their relationship. We addressed this challenge through a dual-process isolation procedure that
Publikováno v:
Cancer Research. 82:B005-B005
Evolution of chemotherapeutic resistance can cause treatment failure in patients with metastatic Ewings sarcoma (EWS). As resistance to the first-line therapy evolves, there is potential for the tumor to develop sensitivities to other chemotherapeuti